Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01FBS
|
|||
| Former ID |
DIB008135
|
|||
| Drug Name |
ALF-5755
|
|||
| Synonyms |
HIP/PAP; Hepatocarcinoma-intestine-pancreas/pancreatic-associated protein
Click to Show/Hide
|
|||
| Indication | Liver failure [ICD-11: DB99.7] | Phase 2 | [1] | |
| Company |
INSERM
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Regenerating human pro-islet peptide (REG3A) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01318525) Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure. U.S. National Institutes of Health. | |||
| REF 2 | HIP/PAP prevents excitotoxic neuronal death and promotes plasticity. Ann Clin Transl Neurol. 2014 October; 1(10): 739-754. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.